

LEUCEMIILE ACUTE LIMFOBLASTICE

Conf. Dr. Arghirescu Smaranda


Introducere (I)

- Prognostic LAL:
 - Diagnostic complet (grupuri de risc)
 - Tratament adaptat grupurilor de risc


Introducere (II)

- 80% din copiii cu LAL sunt supravietuitori de lunga durata
- 1996 – imunofenotipare
- 1998 – citogenetica conventionala +FISH
- 2001 – biologie moleculara
- Tratament
 - nestandardizat
 - protocol ALL BFM 90/95/2000


- Studiu restrospectiv – 314 pacienti (0-18 ani)
- 1981-2006




- Immunofenotipare – 107 pazienti (40%)




- Examen citogenetic clasic – 49% din cazuri



- Anomaliile biomoleculare –analizate la 82 pacienti (26%)
- 24 cazuri – rearanjamente genice




- Protocole de tratament utilizate



Curbe de supravietuire


- pEFS la 3 si 5 ani la pacientii tratati nestandardizat in perioada 1981-1989



EFS LA 3 ANI ~ 40%

EFS LA 5 ANI – 20%


- pEFS la 3 si 5 ani la pacientii tratati conform protocoalelor BFM 90/95 in perioada 1990-1999




EFS LA 3 ANI ~72%

EFS LA 5 ANI ~ 52%


- pEFS la 5 ani la pacientii tratati conform protocoalelor BFM 90/95 in perioada 1990-1999 in raport cu grupele de risc
- Incadrarea in grupe de risc – nu a fost disponibila analiza biomoleculara




- pOS la 5 ani la pacientii tratati conform protocolului BFM 95 in perioada 2000-2006




- pEFS la 5 ani la pacientii tratati conform protocolului BFM 95 in perioada 2000-2006



- pOS la 5 ani la pacientii tratati conform protocolului BFM 95 in perioada 2000-2006 in raport cu grupele de risc



- pEFS la 5 ani la pacientii tratati conform protocolului BFM 95 in perioada 2000-2006 in raport cu grupele de risc



Abateri de la tratament



Abateri	Protocol I	Protocol M	Protocol II
Omiterea sau excluderea unui medicament -L- Asp / Erwinase -Vincristin / Vinblastin -Metotrexat	15	1	15
Reducerea dozei 25% / 1 medicament 50% / 2 medicamente	6	2	6
Spațiere crescută 25% 50% 100% Total	28 5 1 34 pacienți	13 1 0 14 pacienți	24 2 0 26 pacienți

Complicatii



COMPLICAȚII	EPISOADE	%
Cardiace	40	5
Respiratorii	69	9
Renale	10	1
Digestive	125	16
Infecțioase	252	33
Endocrine	6	1
Neuropsihice	11	2
Toxice	72	9
Hematologice	180	24
TOTAL	765	100




4

COMPLICAȚII	NUMĂR	PROCENT
Hepatită toxică	27	17
Neuropatie periferică	11	7
Alergie	18	12
Cardiomiopatie	40	26
Tubulopatie complexă	2	1
Tulburare psihică	2	1
Complicație metabolică	9	6
TOTAL	109	70



Analiza deceselor



- Imbunatatirea ratei de curabilitate este definitiv influentata de conduita terapeutica
- Cresterea ratelor de supravietuire (EFS)
 - 1981-1989 : 20%
 - 1990-1999: 52%
 - 2000-2006: 61%